Profil de l'entreprise pour ULTIMOVACS AS DK1 Action
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Analyse IA de ULTIMOVACS AS DK1
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent
Dernières analyses d’IA sur ULTIMOVACS AS DK1
Aucun fil IA disponible pour cette entreprise pour le moment.